Pfizer reports Q1 results above consensus, reaffirms 2026 guidance
Pfizer rose in premarket trading after it reported earnings results that beat Wall Street expectations and reaffirmed its annual guidance.
For the first three months of 2026, Pfizer reported:
Revenue at $14.5 billion, greater than the $13.8 billion analysts polled by FactSet were expecting. Growth in some of its newer treatments helped offset the decline in demand for its COVID-19 products, it said.
Adjusted earnings per share of $0.75, higher than the $0.72 the Street was penciling in.
For the full year 2026, Pfizer still expects:
Annual adjusted earnings per share to land between $2.80 and $3.00, compared to the $2.96 analysts are currently expecting.
Annual revenues to hit between $59.5 billion and $62.5 billion, compared with the $61.3 billion analysts have forecast.
The pharmaceutical giant is working to reignite growth after demand for its COVID-19 products has waned and as some of its biggest moneymakers get nearer to the end of their patents’ lives. It has made investments in oncology and late last year it acquired Metsera, a biotech working on a once-monthly GLP-1 shot.